Last updated on January 2019

Arnuity Ellipta Drug Use Investigation


Brief description of study

The aim of this post-marketing investigation is to collect and assess the information about safety and effectiveness of ARNUITY ELLIPTA (hereinafter referred to as "Arnuity") in daily clinical practice. The investigation will include subjects with a diagnosis of asthma bronchial who are nave to ARNUITY. The investigator will monitor the information about safety and effectiveness of ARNUITY for one year from the start date of ARNUITY administration and Pneumonia will be considered as the priority investigation matter. 300 subjects, from approximately 150 medical institutions, will be included in this analysis. ARNUITY ELLIPTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.

Clinical Study Identifier: NCT03184480

Find a site near you

Start Over